- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Rancho Cucamonga Today
By the People, for the People
Amphastar Pharmaceuticals Shares Drop After Analyst Downgrade
Needham & Company cuts price target for the specialty pharmaceutical company
Published on Feb. 27, 2026
Got story updates? Submit your updates here. ›
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) fell sharply on Friday after Needham & Company LLC downgraded the stock and lowered its price target. The stock opened at $22.44, down from the previous close of $26.49, following the analyst's move to cut the price target from $34 to $30 while maintaining a buy rating.
Why it matters
Amphastar Pharmaceuticals is a specialty pharmaceutical company focused on developing and manufacturing injectable and inhalation products. The company's stock performance and analyst coverage can impact investor sentiment and the overall outlook for the business.
The details
Needham & Company cited unspecified factors in its decision to lower the price target on Amphastar Pharmaceuticals. The stock has traded in a range of $22.70 to $26.49 so far on the day. Several other analysts have a hold rating on the stock, with an average price target of $30.33.
- Amphastar Pharmaceuticals shares fell on Friday, February 27, 2026.
The players
Amphastar Pharmaceuticals
A specialty pharmaceutical company headquartered in Rancho Cucamonga, California that focuses on developing and manufacturing injectable and inhalation products.
Needham & Company LLC
An investment banking and asset management firm that provides research coverage on Amphastar Pharmaceuticals.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
The downgrade by Needham & Company highlights the volatility and uncertainty surrounding Amphastar Pharmaceuticals' stock performance, underscoring the importance of careful analysis and diversification for investors in the specialty pharmaceutical sector.
